{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670321295731456.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.jacc.2015.01.044"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0735109715004337?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0735109715004337?httpAccept=text/plain"}}],"dc:title":[{"@value":"Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With 0 or 1 Stroke Risk Factor Based on the CHA2DS2-VASc Score"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670321295731459","@type":"Researcher","foaf:name":[{"@value":"Gregory Y.H. Lip"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321295731456","@type":"Researcher","foaf:name":[{"@value":"Flemming Skjøth"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321295731457","@type":"Researcher","foaf:name":[{"@value":"Lars Hvilsted Rasmussen"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670321295731458","@type":"Researcher","foaf:name":[{"@value":"Torben Bjerregaard Larsen"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"07351097"}],"prism:publicationName":[{"@value":"Journal of the American College of Cardiology"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2015-04","prism:volume":"65","prism:number":"14","prism:startingPage":"1385","prism:endingPage":"1394"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license","http://www.elsevier.com/open-access/userlicense/1.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0735109715004337?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0735109715004337?httpAccept=text/plain"}],"createdAt":"2015-03-11","modifiedAt":"2025-10-09","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1361131414221951872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1361975846302236800","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Risks of Bleeding and Stroke Based on CHA2DS2‐VASc Scores in Japanese Patients With Atrial Fibrillation: A Large‐Scale Observational Study Using Real‐World Data"}]},{"@id":"https://cir.nii.ac.jp/crid/1390861305854216192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Investigation of Stroke Risk Factors and Prognostic Indicators in NVAF Patients with Low CHA<sub>2</sub>DS<sub>2</sub>-VASc Scores"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.jacc.2015.01.044"},{"@type":"CROSSREF","@value":"10.1536/ihj.23-236_references_DOI_T7I8d25j0BtCv5ci8p7IwfSUS1b"},{"@type":"CROSSREF","@value":"10.1001/jamacardio.2018.4729_references_DOI_T7I8d25j0BtCv5ci8p7IwfSUS1b"},{"@type":"CROSSREF","@value":"10.1161/jaha.119.014574_references_DOI_T7I8d25j0BtCv5ci8p7IwfSUS1b"}]}